MINIject S: How it Influences Surgical Results and Patient Selection

Show Description +

Tim Schultz, MD, PhD, FEBO, reviews data behind the safety and efficacy of the MINIject supraciliary MIGS device (iStar Medical) during a symposium at the European Glaucoma Society meeting. He shares his experience with the device and its outcome data demonstrating meaningful IOP reduction, mean reduction in medication, and minimal endothelial cell loss.

Posted: 7/16/2024

Up Next

Question and Answer: MINIject Supraciliary MIGS Device

Joseph F. Panarelli, MD; Leon Au, BSc, MBBS, FRCOphth; and Tim Schultz, MD, PhD, FEBO


STAR-GLOBAL 3-Year Results

I. Paul Singh, MD

Q&A: MINIject Supraciliary MIGS Device

Steven R. Sarkisian Jr, MD; Karsten Klabe, MD; Faisal Ahmed, MD; and I. Paul Singh, MD

Full Webinar: An Eye-Opening Update on MIGS

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

European STAR-II Trial Results at One Year

Julián García-Feijoó, MD, PhD

Webinar Part 1: Where Do We Stand With MIGS?

Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 2: How Can We Leverage the Power of the Supraciliary Space?

Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD, Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC

Webinar Part 3: The MINIject™ Next-Generation Supraciliary Device

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Webinar Part 6: Clinical Trial Results Q&A and Next Steps

Inder Paul Singh, MD, Iqbal Ike K. Ahmed, MD, FRCSC, Julián García-Feijoó, MD, PhD, Philippe Denis, MD, PhD

Enhanced and Sustained IOP reduction with MINIject

Iqbal Ike K. Ahmed, MD, FRCSC, Michel Vanbrabant, Steven Vold, MD

Consider the Supraciliary Space With MINIject

Joseph F. Panarelli, MD; and I. Paul Singh, MD

MINIject S: How it Influences Surgical Results and Patient Selection

Tim Schultz, MD, PhD, FEBO, reviews data behind the safety and efficacy of the MINIject supraciliary MIGS device (iStar Medical) during a symposium at the European Glaucoma Society meeting. He shares his experience with the device and its outcome data demonstrating meaningful IOP reduction, mean reduction in medication, and minimal endothelial cell loss.

Posted: 7/16/2024

About iSTAR Medical

Visit us online: istarmed.com

Follow iSTAR Medical